Simultaneous HPLC determination of alfuzosin, tamsulosin and vardenafil in human plasma and pharmaceutical formulations using time programmed fluorescence detection.

[1]  C. Roehrborn,et al.  α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different? , 2016, Advances in Therapy.

[2]  E. Souaya,et al.  SPECTROPHOTOMETRIC METHODS FOR SIMULTANEOUS DETERMINATION OF VARDENAFIL AND DAPOXETINE HYDROCHLORIDES IN COMBINED DOSAGE FORM , 2015 .

[3]  Elisa A Nickum,et al.  Determination of phosphodiesterase-5 inhibitors and analogs using high-performance liquid chromatography with ultraviolet detection. , 2015, Journal of chromatographic science.

[4]  M. Reddy,et al.  Method Development and Validation of Alfuzosin HCl and Dutasteride in Pharmaceutical Dosage Form by RP-HPLC , 2015 .

[5]  Nan Li,et al.  The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. , 2014, The journal of sexual medicine.

[6]  S. T. Ulu,et al.  Validated spectrofluorimetric method for the determination of tamsulosin in spiked human urine, pure and pharmaceutical preparations. , 2014, Luminescence (Chichester, England Print).

[7]  Gao Su-y.  Determination of tamsulosin and the intermediates in its raw material drug and sustained release capsules by capillary zone electrophoresis , 2014 .

[8]  M. Amanlou,et al.  Validated Spectrophtometric Method for Determination of Tamsulosin in Bulk and Pharmaceutical Dosage Forms , 2014, Iranian journal of pharmaceutical research : IJPR.

[9]  J. Ferguson,et al.  Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons , 2013, Arab journal of urology.

[10]  S. Glina,et al.  Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction , 2013, Therapeutic advances in urology.

[11]  Adibah M. Almutairi,et al.  Kinetic spectrophotometric methods for the determination of alfuzosin hydrochloride in bulk and pharmaceutical formulations , 2013, Journal of Analytical Chemistry.

[12]  C. Sekaran,et al.  RP-HPLC METHOD FOR THE ESTIMATION OF TAMSULOSIN IN BULK AND CAPSULES , 2013 .

[13]  S. Ashour,et al.  Conductometric Titration Method for Determination of Alfuzosin Hydrochloride and Fexofenadine Hydrochloride Using Sodium Tetraphenylborate , 2013 .

[14]  C. Jang,et al.  Determination of tamsulosin in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[15]  C. Roehrborn,et al.  A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. , 2012, European urology.

[16]  G. S. Kumar,et al.  Stability-Indicating RP-HPLC Method for Determination of Tamsulosin HCL in Pharmaceutical Dosage Form , 2012, Journal of basic and clinical pharmacy.

[17]  S. Kshirsagar,et al.  Development, validation and Comparative statistical Evaluation of HPLC and HPTLC method for determination of Alfuzosin in Human plasma , 2012 .

[18]  S. Bari,et al.  HPTLC Method Validation for simultaneous determination of Tamsulosin Hydrochloride and Finasteride in Bulk and Pharmaceutical Dosage Form , 2011 .

[19]  P. Kumar,et al.  RP HPLC Method for the determination of Tamsulosin in bulk and Pharmaceutical formulations , 2011 .

[20]  X. de la Torre,et al.  A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine. , 2010, Rapid communications in mass spectrometry : RCM.

[21]  R. Addison,et al.  Validated LC-MS/MS assay for the quantitative determination of vardenafil in human plasma and its application to a pharmacokinetic study. , 2009, Biomedical chromatography : BMC.

[22]  P. Iuliani,et al.  Development of a method for the determination of vardenafil in human plasma by high performance liquid chromatography with UV detection. , 2009, Biomedical chromatography : BMC.

[23]  C. Chou,et al.  Development and validation of a high-performance liquid chromatographic method using fluorescence detection for the determination of vardenafil in small volumes of rat plasma and bile. , 2007, Journal of chromatography. A.

[24]  A. M. Idris,et al.  Multi-response optimization of a capillary electrophoretic method for determination of vardenafil in the bulk drug and in a tablet formulation , 2007 .

[25]  M. Elhilali,et al.  Vardenafil in patients with erectile dysfunction: achieving treatment optimization. , 2005, Journal of andrology.

[26]  A. Ghanem,et al.  Determination of Vardenafil in Pharmaceutical Formulation by HPLC Using Conventional C18 and Monolithic Silica Columns , 2005 .

[27]  W. Krauwinkel,et al.  The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS , 2005 .

[28]  R. Mongeau,et al.  Evaluation of Tamsulosin and Alfuzosin Activity in the Rat Vas Deferens: Relevance to Ejaculation Delays , 2005, Journal of Pharmacology and Experimental Therapeutics.

[29]  J. Miller,et al.  Statistics and chemometrics for analytical chemistry , 2005 .

[30]  E. Bischoff,et al.  Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events , 2004, International Journal of Impotence Research.

[31]  C. Roehrborn.  Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. , 2001, Urology.